Björklund Pharma

  • Home
  • Company
  • Science & Innovation
  • Publications
  • Media
  • Contact
    • Contact Form

Psychiatry

Product Candidate

Fabomotizole: A Third-Generation Anxiolytic Drug

Fabomotizole (4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine) is an anxiolytic drug that produces anxiolytic and neuroprotective effects without significantly sedative, hypnotic, or muscle relaxant properties.

The drug eliminates the manifestations of anxiety and stress and stabilizes the structure of corresponding receptors, restores the normal sensitivity of nerve cell receptors, and protects against further stress. The action of fabomotizole is through sigma-agonistic, melatonergic, indirect GABAergic, membrane-stabilizing, and weak MAO-A inhibitor activities.

Fabomotizole is not an agonist of benzodiazepine or barbiturate sites of GABA receptors. Thus, it does not have the classical drawbacks of those well-known classes of anxiolytics. The drug has no negative impact on the ability to drive vehicles and perform potentially dangerous activities requiring increased attention concentration and speed of psychomotor reactions.

Fabomotizole has few side effects. Allergic reactions are possible. Rarely a headache occurs, which usually resolves on its own and does not require discontinuation of the drug. A significant overdose can cause a sedative effect and increased drowsiness without manifestations of muscle relaxation.

Recent Posts

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment
  • Email
  • Facebook
  • Google+
  • LinkedIn
  • Twitter
  • YouTube

RSS CONEM News

  • DAJTEMU
  • Better Brain Health – We Are What We Eat
  • Zinc, Copper, and Autism Spectrum Disorder
  • Nutritional Minerals and the Periodic Table
  • Semey Revisited: The legacy of nuclear testing in Kazakhstan

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2023 Björklund Pharma AS